Nitric oxide (SB 206)

Drug Profile

Nitric oxide (SB 206)

Alternative Names: NVN-1000 SB-206; SB-206

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Novan Inc
  • Class Antiacnes; Antiandrogens; Antibacterials; Antihypertensives; Antivirals; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Angiogenesis inducing agents; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Genital warts; Human papillomavirus infections
  • Discontinued Staphylococcal infections

Most Recent Events

  • 29 Nov 2016 Novan plans pivotal phase III trial for Genital warts in USA
  • 29 Nov 2016 Efficacy and adverse events data from a phase II trial in Genital warts released by Novan
  • 14 Nov 2016 Novan completes enrolment in its phase II trial for Genital warts in USA (NCT02462187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top